Ocular Therapeutix Inc
OCUL
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.43B
Close$
$-1.59
114.5% downside
Current Fair Value
114.5% downsideOvervalued by 114.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.43 Billion |
|---|---|
| Enterprise Value | $1.91 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.42 |
| Beta | 0.94 |
| Outstanding Shares | 224,952,428 |
Return
| Return on Equity | -57.97% |
|---|---|
| Return on Assets | -44.90% |
| Return on Invested Capital | -49.31% |
Valuation & Multiples
| P/E Ratio | -7.8 |
|---|---|
| PEG | -48.33 |
| Price to Sales | - |
| Price to Book Ratio | 5.51 |
| Enterprise Value to Revenue | 36.63 |
| Enterprise Value to EBIT | -6.22 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$13.20 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$14.32 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2943▼ 74.55% |
|---|---|
| Total Calls | 1,987,500▼ 8.53% |
| Total Puts | 584,900▼ 74.11% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 92.82%▼ 17.62% |
|---|---|
| Total Invested | $2.18B▲ 23.36% |
| Investors Holding | 273▼ 14.00% |
ESG Score
No data
About Ocular Therapeutix Inc
CEO: Antony Mattessich